Dosages
Side effects in children
Warnings & precautions in children
Contra-indications in children

Interactions
PK
Renal impairment
References

Meningococcen C vaccin

Generic name
Meningococcen C vaccin
Brand name
ATC Code
J07AH07

Pharmacokinetics in children

Not applicable

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

dose recommendation of formulary compared to licensed use (on-label versus off-label)

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Available formulations

No information is present at this moment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Dosages

Vaccination against invasive meningococcal diseases caused by Neisseria meningitidis groups C
  • Intramuscular
    • ≥ 2 years
      [1]

      • NEISVAC-C

        • 2-4 months: 0.5 ml/dose
          Vaccination schedule as follows:
          1 vaccination: any time, independent of age
          2nd vaccination: at least 2 months after 1st vaccination
          It is recommended that a booster dose be administered at 12-13 months of age with an interval of at least 6 months after the last vaccination.
        • ≥ 4 months: 0.5 ml/dose single dose

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Renal impaiment in children > 3 months

No information available on dose adjustment in renal impairment.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all undesirable drug reactions can be found in the national Summary of Product Characteristics (SmPC) – click here

Side effects in children

Children 2-17 months
Very common (> 10%): redness, local pain and edema at injection site. Irritability, fatigue, fever. Vomiting. Crying, drowsiness, sedation. Decreased appetite.

Common (1-10%): pharyngitis, rhinitis. Agitation, restlessness, sleep disturbance. Coughing. Diarrhea. Skin rash, hyperhidrosis.

Uncommon (0.1-1%): excessive flushing. Abdominal pain, dyspepsia. Redness. Pain in extremity. Peripheral edema, malaise, chills.

Rare (0.1-0.01%): hypersensitivity (including bronchospasm). Eyelid edema. Circulatory collapses. Ecchymosis. Muscle stiffness (including neck stiffness, joint stiffness).

Children 3.5-17 years
Very common (> 10%): redness, local pain and edema at injection site. Headache.

Common (1-10%): pharyngitis, rhinitis. Dizziness, drowsiness, sedation. Coughing. Nausea, abdominal pain, vomiting, diarrhea. Itching, ecchymosis, dermatitis. Pain in extremity. Fever, malaise, fatigue.

Uncommon (0.1-1%): lymphadenopathy. Hypersensitivity reactions (including bronchospasm). Decreased appetite. Agitation. Sensory disturbances (such as hypoaesthesia, paresthesia, burning sensation), convulsion, syncope, crying. Muscle stiffness, neck pain, muscle pain, arthralgia, back pain. Eyelid edema. Nasal congestion. Skin rash, hyperhidrosis, excessive flushing. Joint pain. Irritability, asthenia, peripheral edema, chills. Flu-like symptoms.

Rare (0.1-0.01%): circulatory collapses.

General
Reported is: recurrent nephrotic syndrome in children.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

The complete list of all contra-indications can be found in the national Summary of Product Characteristics (SmPC) – click here

Contra-indications

No information available on specific contra indications in children.

The complete list of all warnings and precautions can be found in the national Summary of Product Characteristics (SmPC) – click here

Warnings & precautions in children

When administering to very preterm infants (born ≤ week 28 of gestation) consider respiratory monitoring for 48-72 hours because of the potential risk of apnea, especially in children with a history of inadequate lung maturation; since the benefit of vaccination is high in this group of children, do not withhold or delay vaccination.

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Interactions

The complete list of all interactions can be found in the national Summary of Product Characteristics (SmPC) – click here

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Cholera vaccines
J07AE01
Haemophilus influenzae B vaccines
J07AG01
Meningococcal vaccines
J07AH09
J07AH08
Pertussis vaccines
J07AJ52
Pneumococcal vaccines
J07AL02
Tuberculosis vaccines
J07AN01
Typhoid vaccines
J07AP03
J07AP01

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Reference

  1. Pfizer bv, SmPC NeisVac-C (RVG 26343) 30-05-2021, www.geneesmiddeleninformatiebank.nl

A second drug has not been selected yet.
Press ‘drugs’ followed with and select second drug from list to add the second drug to the comparison.

Changes

Changes